| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/05/2003 | CN1100554C Chinese patent drug for curing gastroptosis |
| 02/05/2003 | CN1100546C Micro-encapsulated lactobacilli for medical applications |
| 02/05/2003 | CN1100536C Composition for rectal administration |
| 02/05/2003 | CN1100535C Pharmaceutical agents for treatment of emesis |
| 02/04/2003 | US6515116 Method of preparing form II crystals of clarithromycin |
| 02/04/2003 | US6515016 Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases |
| 02/04/2003 | US6515005 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 02/04/2003 | US6515004 Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease |
| 02/04/2003 | US6515003 Useful in the treatment of diseases related to lipid and carbohydrate metabolism |
| 02/04/2003 | US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions |
| 02/04/2003 | US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase |
| 02/04/2003 | US6514977 For treating p38 kinase mediated disorders |
| 02/04/2003 | US6514976 Arylpiperazines having activity at the serotonin 1A receptor |
| 02/04/2003 | US6514975 Anti-inflammatory piperazinyl-benzyl-tetrazole derivatives and intermediates thereof |
| 02/04/2003 | US6514968 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising |
| 02/04/2003 | US6514960 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 02/04/2003 | US6514738 Given amino acid sequence; microtubular depolymerization activity in presence of ATP; can be used in diagnosis and treatment of cancer, neurological and vesicular transport disorders. |
| 02/04/2003 | US6514494 Bacterial strain, processed plant extracts, compostions containing same, processes for their preparation and their therapeutic and industrial applications |
| 02/04/2003 | US6514484 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
| 01/30/2003 | WO2003008579A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 01/30/2003 | WO2003008560A2 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | WO2003008548A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 01/30/2003 | WO2003008446A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008425A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | WO2003008414A1 Chemical compounds |
| 01/30/2003 | WO2003008412A2 Hetero-bicyclic crf antagonists |
| 01/30/2003 | WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 01/30/2003 | WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008377A1 Prostaglandin analogues_as ep4 receptor agonists |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | WO2003007991A1 Pancreatic juice secretion regulators comprising lpa receptor controller |
| 01/30/2003 | WO2003007989A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | WO2003007981A1 Methods of treating liver fibrosis |
| 01/30/2003 | WO2003007980A1 Phosphinate-peptide analogues as inhibitors of procollagen-c-proteinase (pcp) for treating fibrotic diseases |
| 01/30/2003 | WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 01/30/2003 | WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | WO2003007922A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | WO2003007917A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | WO2003007907A1 Water-free ubichinon concentrate |
| 01/30/2003 | WO2003007890A2 Tropomyosin isoforms, and diagnostic and therapeutic uses therefor |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007800A2 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002092756A3 Insulin producing cells derived from human embryonic stem cells |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002080939A8 Ionene polymers and their use as antimicrobial agents |
| 01/30/2003 | WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders |
| 01/30/2003 | WO2002070510A3 Amino dicarboxylic acid derivatives with pharmaceutical properties |
| 01/30/2003 | WO2002066002A3 Pharmaceutical formulation |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002060449A3 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates |
| 01/30/2003 | WO2002059129A3 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 01/30/2003 | WO2002053097A3 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/30/2003 | WO2002018375A1 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof |
| 01/30/2003 | WO2002018351A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 01/30/2003 | WO2002014356A3 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 01/30/2003 | WO2002013836A1 Preventive or therapeutic drugs for cancers containing cyanidin compounds as the active ingredient |
| 01/30/2003 | WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001093849A3 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030023993 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation |
| 01/30/2003 | US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc. |
| 01/30/2003 | US20030023098 Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| 01/30/2003 | US20030023091 For therapy and prophylaxis of peptic ulcers, gastro intestinal inflammatory diseases like duodenal/ gastric ulcer or gastritis or other gastro intestinal disorders |
| 01/30/2003 | US20030023085 For therapy and prophylaxis of condition or disorder mediated by a G-protein coupled receptor such as eating disorders, obesity, anxiety disorders and mood disorders |
| 01/30/2003 | US20030023070 For diagnosis, prophylaxis and therapy; therapy of cancer |
| 01/30/2003 | US20030023038 For therapy of undesired cell proliferation; for stimulation and inhibition of lymphocytes |
| 01/30/2003 | US20030023033 Novel class II cytokine receptors and uses thereof |
| 01/30/2003 | US20030022942 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022934 For therapy and prophylaxis of pain and/or neurodegenerative disorders |
| 01/30/2003 | US20030022933 Administering to the patient a cathartic- inducing effective amount of halogenated bioactive lipid |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022904 Pyrazine compounds |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022898 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) |
| 01/30/2003 | US20030022897 Use of cox-2 inhibitors as gastroprokinetics |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |